{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Peritoneum+Cancer&page=2", "query": { "condition": "Peritoneum Cancer", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Peritoneum+Cancer&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-06-25T17:21:02.633Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05080946", "title": "Using Aspirin to Improve Immunological Features of Ovarian Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Ovarian Cancer", "Fallopian Tube Cancer", "Peritoneal Cancer" ], "interventions": [ { "name": "Aspirin 325mg", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 100, "start_date": "2021-11-02", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2026-04-01", "last_synced_at": "2026-06-25T17:21:02.633Z", "location_count": 4, "location_summary": "Tampa, Florida • Portland, Oregon • Charlottesville, Virginia + 1 more", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Portland", "state": "Oregon" }, { "city": "Charlottesville", "state": "Virginia" }, { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05080946" }, { "nct_id": "NCT06161025", "title": "A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Solid Cancer" ], "interventions": [ { "name": "R-DXd", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Topotecan", "type": "DRUG" }, { "name": "PLD", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 860, "start_date": "2024-02-27", "completion_date": "2030-04-30", "has_results": false, "last_update_posted_date": "2026-05-22", "last_synced_at": "2026-06-25T17:21:02.633Z", "location_count": 43, "location_summary": "Anchorage, Alaska • New Haven, Connecticut • Coral Gables, Florida + 32 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Coral Gables", "state": "Florida" }, { "city": "Deerfield Beach", "state": "Florida" }, { "city": "Lake Mary", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06161025" }, { "nct_id": "NCT00268918", "title": "Docetaxel and PTK787 in Metastatic Breast Cancer Patients and Gynecological Cancer Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Ovarian Cancer", "Endometrial Cancer", "Cervical Cancer", "Fallopian Tube Cancer", "Peritoneal Cancer", "Breast Cancer" ], "interventions": [ { "name": "Docetaxel", "type": "DRUG" }, { "name": "PTK787", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 24, "start_date": "2005-09", "completion_date": "2011-01", "has_results": false, "last_update_posted_date": "2018-07-27", "last_synced_at": "2026-06-25T17:21:02.633Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00268918" }, { "nct_id": "NCT03138408", "title": "SC-004 Alone or With ABBV-181 in Subjects With Epithelial Ovarian, Fallopian Tube, Primary Peritoneal and Endometrial Cancers", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "SC-004", "type": "DRUG" }, { "name": "ABBV-181", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 24, "start_date": "2017-06-14", "completion_date": "2019-05-02", "has_results": false, "last_update_posted_date": "2019-05-14", "last_synced_at": "2026-06-25T17:21:02.633Z", "location_count": 12, "location_summary": "Birmingham, Alabama • Fayetteville, Arkansas • Duarte, California + 9 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Duarte", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT03138408" }, { "nct_id": "NCT03673124", "title": "Ribociclib and Letrozole Treatment in Ovarian Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Low Grade Serous Carcinoma" ], "interventions": [ { "name": "Ribociclib", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gynecologic Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 51, "start_date": "2019-05-20", "completion_date": "2026-12-31", "has_results": true, "last_update_posted_date": "2025-12-23", "last_synced_at": "2026-06-25T17:21:02.633Z", "location_count": 27, "location_summary": "San Francisco, California • Gainesville, Florida • Tampa, Florida + 19 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Evanston", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03673124" }, { "nct_id": "NCT00310076", "title": "Thalidomide in Treating Patients Who Have Undergone Surgery and Chemotherapy for Cancer That Has Spread Throughout the Abdomen Due to Colorectal Cancer or Appendix Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinoma of the Appendix", "Colorectal Cancer" ], "interventions": [ { "name": "thalidomide", "type": "DRUG" }, { "name": "surgery", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Wake Forest University Health Sciences", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 29, "start_date": "2002-10", "completion_date": "2012-09", "has_results": true, "last_update_posted_date": "2018-08-23", "last_synced_at": "2026-06-25T17:21:02.633Z", "location_count": 1, "location_summary": "Winston-Salem, North Carolina", "locations": [ { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00310076" }, { "nct_id": "NCT05271318", "title": "Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer.", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Platinum-refractory Ovarian Carcinoma", "Platinum-resistant Ovarian Cancer", "Platinum-Resistant Fallopian Tube Carcinoma", "Platinum-Resistant Primary Peritoneal Carcinoma", "Platinum-Refractory Fallopian Tube Carcinoma", "Platinum-Refractory Primary Peritoneal Carcinoma", "Platinum-Sensitive Ovarian Cancer in Which the Participant Has Allergy or Severe Intolerance to Carboplatin and/or Cisplatin", "Platinum-Sensitive Fallopian Tube Carcinoma in Which the Participant Has Allergy or Severe Intolerance to Carboplatin and/or Cisplatin", "Platinum-Sensitive Primary Peritoneal Carcinoma in Which the Participant Has Allergy or Severe Intolerance to Carboplatin and/or Cisplatin" ], "interventions": [ { "name": "TILT-123", "type": "BIOLOGICAL" }, { "name": "pembrolizumab", "type": "BIOLOGICAL" }, { "name": "pegylated liposomal doxorubicin", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "TILT Biotherapeutics Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 29, "start_date": "2022-05-17", "completion_date": "2027-08", "has_results": false, "last_update_posted_date": "2026-05-05", "last_synced_at": "2026-06-25T17:21:02.633Z", "location_count": 2, "location_summary": "Rochester, Minnesota • New York, New York", "locations": [ { "city": "Rochester", "state": "Minnesota" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05271318" }, { "nct_id": "NCT07291180", "title": "A Feasibility Study of Mass-Based Response Drug Screening to Guide Personalized Hyperthermic Intraperitoneal Chemotherapy for High-Grade Appendiceal and Colorectal Adenocarcinoma With Peritoneal Metastasis", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Appendiceal Cancer", "Colorectal Adenocarcinoma", "Peritoneal Metastases" ], "interventions": [ { "name": "Mass-based response testing (MRT)", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Yale University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "81 Years", "sex": "ALL", "summary": "18 Years to 81 Years" }, "enrollment_count": 20, "start_date": "2026-02-17", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2026-06-22", "last_synced_at": "2026-06-25T17:21:02.633Z", "location_count": 1, "location_summary": "New Haven, Connecticut", "locations": [ { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT07291180" }, { "nct_id": "NCT02188550", "title": "Single Arm Trial With Combination of Everolimus and Letrozole in Treatment of Platinum Resistant Relapse or Refractory or Persistent Ovarian Cancer/Endometrial Cancer", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ovarian Cancer", "Endometrial Cancer" ], "interventions": [ { "name": "everolimus and letrozole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sinai Hospital of Baltimore", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "FEMALE", "summary": "18 Years to 80 Years · Female only" }, "enrollment_count": 20, "start_date": "2014-06", "completion_date": null, "has_results": false, "last_update_posted_date": "2015-05-19", "last_synced_at": "2026-06-25T17:21:02.633Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02188550" }, { "nct_id": "NCT00317772", "title": "Topotecan and Gefitinib (Iressa) for Ovarian, Peritoneal, or Fallopian Tube Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Ovarian Cancer", "Peritoneal Neoplasms", "Fallopian Tube Cancer" ], "interventions": [ { "name": "Topotecan", "type": "DRUG" }, { "name": "Gefitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "FEMALE", "summary": "Female only" }, "enrollment_count": 19, "start_date": "2004-09-02", "completion_date": "2020-11-04", "has_results": true, "last_update_posted_date": "2022-02-07", "last_synced_at": "2026-06-25T17:21:02.633Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00317772" } ] }